热门资讯> 正文
Twist Bioscience在超过200万美元的内幕交易后下跌
2026-02-20 22:21
- Twist Bioscience (TWST) lost ~7% in the premarket on Friday after its Senior Vice President of Human Resources, Paula Green, sold more than $2M worth of company stock.
- Green, who has served the DNA-based product for nearly a decade, disclosed the transaction in a regulatory filing on Thursday.
- According to the filing, she sold more than 39.4K Twist Bioscience (TWST) shares on Tuesday for an average price of $52.40 apiece. The transaction, worth nearly $2.1M, has lowered her stake in Twist (TWST) by 24% to roughly 126.0K shares.
- The sale comes after shares of the San Francisco, California-based biotech climbed more than 65% this year, including nearly 14% on Feb. 2 in reaction to a guidance hike issued with the company’s Q1 FY26 results.
More on Twist Bioscience
- Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
- Twist Bioscience Corporation (TWST) Shareholder/Analyst Call - Slideshow
- Twist Bioscience: Liquid Biopsy And AI Tailwinds
- Twist Bioscience rises on licensing deal for antibody discovery platform
- Twist Bioscience outlines $435M–$440M 2026 revenue target while accelerating AI-enabled discovery investments
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
